We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
Read MoreHide Full Article
Key Takeaways
HealthEquity Q2 EPS of $1.08 beat estimates and rose 25.6% Y/Y, with GAAP EPS up 70% Y/Y.
Quarterly revenues grew 8.6% to $325.8M, driven by gains in custodial and interchange revenues.
Total HSA assets hit $33.1B, up 12% Y/Y, with 10M HSAs and 782,000 invested accounts reported.
HealthEquity, Inc. (HQY - Free Report) reported adjusted earnings per share (EPS) of $1.08 for second-quarter fiscal 2026, surpassing the Zacks Consensus Estimate by 17.4%. The bottom line improved 25.6% on a year-over-year basis.
GAAP EPS in the fiscal second quarter was 68 cents, up 70% compared with the year-ago quarter’s EPS.
Shares of HQY were up 3.7% in after-market trading following the earnings call.
HealthEquity Revenues in Detail
In the fiscal second quarter, the company generated revenues of $325.8 million, which beat the Zacks Consensus Estimate by 2.2%. The top line improved 8.6% from the prior-year quarter.
HSA Details of HQY
As of July 31, 2025, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10 million, up 6% year over year.
HealthEquity reported 782,000 HSAs with investments as of July 31, 2025, up 10% year over year. Total accounts, as of July 31, 2025, were 17.1 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs).
Total HSA assets were $33.1 billion at the end of July 31, 2025, up 12% year over year. This included $17 billion of HSA cash and $16.1 billion of HSA investments. This figure compares to our fiscal second-quarter HSA cash and HSA investments projection of $18.3 billion and $13.5 billion, respectively. We had projected total HSA assets of $31.9 billion for the fiscal second quarter.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $0.8 billion as of July 31, 2025.
Revenue Sources of HealthEquity
HealthEquity derives revenues from three sources: Service revenues, Custodial revenues, and Interchange revenues.
Service revenues totaled $117.9 million in the quarter, up 0.9% year over year. This reflected a higher number of HSAs and invested HSA Assets. This figure compares favorably with our second-quarter projection of $121.9 million.
Custodial revenues totaled $159.9 million, up 15.3% from the year-ago period. Our projection for the fiscal second-quarter Custodial revenues was $140.4 million.
Interchange revenues totaled $48.1 million, up 8% year over year. This figure compares favorably with our fiscal second-quarter projection of $52 million.
HQY Margin Details
In the quarter under review, HealthEquity’s gross profit rose 13.9% year over year to $232.6 million. The gross margin expanded 340 basis points (bps) to 71.4%. We had projected the gross margin to be 63.2% in the fiscal second quarter.
Sales and marketing expenses declined 7.5% to $19.9 million year over year, whereas technology and development expenses climbed 10.6% year over year to $64.8 million. General and administrative expenses decreased 7% year over year to $29.9 million. Total operating expenses of $142.9 million decreased 1.5% year over year.
Operating profit totaled $89.6 million, improving significantly by 52.1% from the prior-year quarter. The operating margin in the quarter expanded by a huge 790 bps to 27.5% compared with the prior-year quarter.
HealthEquity, Inc. Price, Consensus and EPS Surprise
The company exited the second quarter of fiscal 2026 with cash and cash equivalents of $304.5 million compared with $287.9 million at the first quarter of fiscal 2026-end. Total debt (net of issuance costs) at the end of second-quarter fiscal 2026 was $1.01 billion compared with $1.06 billion at the end of first-quarter fiscal 2026.
Cumulative net cash provided by operating activities at the end of second-quarter fiscal 2026 totaled $200.6 million compared with $173.6 million a year ago.
HealthEquity FY26 Guidance
HealthEquity has updated its revenue and EPS projections for fiscal 2026.
For fiscal 2026, revenues are now projected to be between $1.290 billion and $1.310 billion compared with the previous guidance of $1.285 billion and $1.305 billion. The Zacks Consensus Estimate is currently pegged at $1.30 billion.
Adjusted EPS is now expected to be in the range of $3.74-$3.91 compared with the previous guidance of $3.61-$3.78. The Zacks Consensus Estimate currently stands at $3.73.
Our Take on HQY
HealthEquity exited second-quarter fiscal 2026 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Significant improvements in operating and gross margins also bode well.
Management emphasized that HealthEquity opened 163,000 new HSAs in the quarter, supported by strong new enterprise wins, client retention and growing adoption of HSA-qualified health plans among SMBs. They also pointed to momentum from upsell and cross-sell opportunities, improved data analytics, and increased member engagement through tools like the analyzer platform. In addition, expanded use of the secure mobile app and AI-driven expedited claims processing contributed to better member experience, higher satisfaction, and reduced costs, all factors that are helping drive revenue growth.
On the other hand, management also acknowledged that the broader labor market remains under pressure, with job growth down 40% year to date compared to last year. Since HSA growth is closely tied to employment trends and workforce mobility, this macro softness has limited the pace of new account openings. While the company is leaning into its sales pipeline and marketing efforts to offset these headwinds, it acknowledged that HSA openings remain more muted than it would prefer, given the current environment.
Zacks Rank & Key Picks
Currently, HealthEquity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
Key Takeaways
HealthEquity, Inc. (HQY - Free Report) reported adjusted earnings per share (EPS) of $1.08 for second-quarter fiscal 2026, surpassing the Zacks Consensus Estimate by 17.4%. The bottom line improved 25.6% on a year-over-year basis.
GAAP EPS in the fiscal second quarter was 68 cents, up 70% compared with the year-ago quarter’s EPS.
Shares of HQY were up 3.7% in after-market trading following the earnings call.
HealthEquity Revenues in Detail
In the fiscal second quarter, the company generated revenues of $325.8 million, which beat the Zacks Consensus Estimate by 2.2%. The top line improved 8.6% from the prior-year quarter.
HSA Details of HQY
As of July 31, 2025, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10 million, up 6% year over year.
HealthEquity reported 782,000 HSAs with investments as of July 31, 2025, up 10% year over year. Total accounts, as of July 31, 2025, were 17.1 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs).
Total HSA assets were $33.1 billion at the end of July 31, 2025, up 12% year over year. This included $17 billion of HSA cash and $16.1 billion of HSA investments. This figure compares to our fiscal second-quarter HSA cash and HSA investments projection of $18.3 billion and $13.5 billion, respectively. We had projected total HSA assets of $31.9 billion for the fiscal second quarter.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $0.8 billion as of July 31, 2025.
Revenue Sources of HealthEquity
HealthEquity derives revenues from three sources: Service revenues, Custodial revenues, and Interchange revenues.
Service revenues totaled $117.9 million in the quarter, up 0.9% year over year. This reflected a higher number of HSAs and invested HSA Assets. This figure compares favorably with our second-quarter projection of $121.9 million.
Custodial revenues totaled $159.9 million, up 15.3% from the year-ago period. Our projection for the fiscal second-quarter Custodial revenues was $140.4 million.
Interchange revenues totaled $48.1 million, up 8% year over year. This figure compares favorably with our fiscal second-quarter projection of $52 million.
HQY Margin Details
In the quarter under review, HealthEquity’s gross profit rose 13.9% year over year to $232.6 million. The gross margin expanded 340 basis points (bps) to 71.4%. We had projected the gross margin to be 63.2% in the fiscal second quarter.
Sales and marketing expenses declined 7.5% to $19.9 million year over year, whereas technology and development expenses climbed 10.6% year over year to $64.8 million. General and administrative expenses decreased 7% year over year to $29.9 million. Total operating expenses of $142.9 million decreased 1.5% year over year.
Operating profit totaled $89.6 million, improving significantly by 52.1% from the prior-year quarter. The operating margin in the quarter expanded by a huge 790 bps to 27.5% compared with the prior-year quarter.
HealthEquity, Inc. Price, Consensus and EPS Surprise
HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote
Financial Position of HQY
The company exited the second quarter of fiscal 2026 with cash and cash equivalents of $304.5 million compared with $287.9 million at the first quarter of fiscal 2026-end. Total debt (net of issuance costs) at the end of second-quarter fiscal 2026 was $1.01 billion compared with $1.06 billion at the end of first-quarter fiscal 2026.
Cumulative net cash provided by operating activities at the end of second-quarter fiscal 2026 totaled $200.6 million compared with $173.6 million a year ago.
HealthEquity FY26 Guidance
HealthEquity has updated its revenue and EPS projections for fiscal 2026.
For fiscal 2026, revenues are now projected to be between $1.290 billion and $1.310 billion compared with the previous guidance of $1.285 billion and $1.305 billion. The Zacks Consensus Estimate is currently pegged at $1.30 billion.
Adjusted EPS is now expected to be in the range of $3.74-$3.91 compared with the previous guidance of $3.61-$3.78. The Zacks Consensus Estimate currently stands at $3.73.
Our Take on HQY
HealthEquity exited second-quarter fiscal 2026 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Significant improvements in operating and gross margins also bode well.
Management emphasized that HealthEquity opened 163,000 new HSAs in the quarter, supported by strong new enterprise wins, client retention and growing adoption of HSA-qualified health plans among SMBs. They also pointed to momentum from upsell and cross-sell opportunities, improved data analytics, and increased member engagement through tools like the analyzer platform. In addition, expanded use of the secure mobile app and AI-driven expedited claims processing contributed to better member experience, higher satisfaction, and reduced costs, all factors that are helping drive revenue growth.
On the other hand, management also acknowledged that the broader labor market remains under pressure, with job growth down 40% year to date compared to last year. Since HSA growth is closely tied to employment trends and workforce mobility, this macro softness has limited the pace of new account openings. While the company is leaning into its sales pipeline and marketing efforts to offset these headwinds, it acknowledged that HSA openings remain more muted than it would prefer, given the current environment.
Zacks Rank & Key Picks
Currently, HealthEquity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.